The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...

Triple therapy may improve asthma symptoms, particularly among patients requiring systemic corticosteroids to treat severe exacerbations, a study finds. Adding long-acting muscarinic antagonists ...

Respiratory Drugs Long-acting muscarinic antagonists (LAMA) have been shown to reduce exacerbations of chronic obstructive pulmonary disease (COPD) and are now being considered for patients with ...

Overall results demonstrated that for the LABA/LAMA cohort cardiovascular event frequency was 2.11% compared to 3.41% in the LABA/ICS cohort. According to a new study published in the Annals of ...

Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...

Triple therapy in COPD significantly improves lung function vs LAMA monotherapy, LABA/LAMA, and ICS/LABA, although evidence showing this is often low quality. Triple therapy is likely effective, safe, ...

INDIANAPOLIS & RIDGEFIELD, Conn.--(BUSINESS WIRE)--The first patients have now enrolled in AIRWISE, the world’s largest ever pragmatic clinical trial in chronic obstructive pulmonary disease (COPD) to ...

Patients with chronic obstructive pulmonary disease (COPD) experienced significantly fewer acute exacerbations when a long-acting muscarinic antagonist (LAMA) was added to a long-acting beta agonist ...

LAMAs were found to be safe and effective in the treatment of COPD and have been recommended by international clinical guidelines for the management of symptoms in COPD. A population-based cohort ...

Basel, May 1, 2020 — Novartis today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval ...

LABA/LAMA is associated with a similar or lower risk of cardiovascular and cerebrovascular adverse events compared to treatment with LABA/inhaled corticosteroid. According to a new study published in ...